Nektar Therapeutics (NKTR) KPIs and segments
Close on Nov 17, 2026Market cap $1.23BP/E –Yield –
KPIs & segments
Operating metrics and segments that drive Nektar Therapeutics's business
Nektar Therapeutics's revenue by segment, product and region, plus the counts and sizes it tags in its 10-K and 10-Q filings (XBRL). Each figure links to the filing it came from. A fuller KPI sheet built from earnings releases and presentations is on the way. See the segment tables for a trailing-twelve-month view, or how companies compare on operating metrics.
The chart is empty. Tick the box next to any metric in the table below to plot it — tick several to compare them on one chart.
| Add to chart | Metric | Q2 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Non-cash royalty revenue related to the sales of future royalties($M) | 10.1 | 21.8 | 11.5 | 11.2 | 10.5 | 16.2 | 15.7 | 16.8 | 15.5 | 18.1 | 18.2 | 15.8 | |
Product sales($M) | 0 | 0 | 0 | 0 | 12.9 | 8.02 | 6.64 | 6.03 | 5.48 | 5.82 | 4.66 | ||
License, collaboration and other revenue($M) | 0 | 0.30 | 0 | 0 | 0.06 | 0.38 | 0.06 | 0.10 | 0.34 | 0.16 | 0.01 | ||
1 metric has no data in the last 12 quarters — .
Italic numbers are calculated by StockData from reported figures (hover for the formula). Numbers with a dotted underline are read from the text of earnings releases and presentations; hover to see the exact sentence. Tick a row to add it to the chart above (up to 8 lines).
Methodology and excluded metrics
- Core rows come from the segment and revenue-disaggregation notes of 10-K and 10-Q filings (XBRL), linked to each filing. Fourth-quarter figures are the fiscal year less the first nine months (shown in italic).
Data updated 2026-08-14.
See a number that looks wrong?